This patent application protects methods used in quantifying biomarker levels in whole blood samples, adding to the current Immunexpress portfolio of 14 patent families, to date of which three have been granted in the US.
Immunexpress has been an early innovator in developing whole-blood, host gene expression biomarkers for differentiating systemic inflammatory conditions caused by infectious and non-infectious agents, resulting in the FDA clearance for SeptiCyte LAB in early 2017.
Immunexpress is committed to improving outcomes for patients suspected of sepsis.
The company's SeptiCyte technology rapidly quantifies, directly from whole blood, specific molecular markers from the patient's own immune system the 'host response'. Its pipeline includes several assays for readily available instruments, including random access, point-of-care and sample-to-answer.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer